|0.72 -0.077 (-9.69%)||12-07 15:15|
|Targets||6-month :||1.26||1-year :||1.57|
|Resists||First :||1.08||Second :||1.35|
|Supports||First :||0.64||Second :||0.54|
|MAs||MA(5) :||0.79||MA(20) :||0.98|
|MA(100) :||1.49||MA(250) :||2.27|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||15.2||D(3) :||20|
|52-week||High :||7.19||Low :||0.05|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADXS ] has closed above bottom band by 16.8%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.85 - 0.86||0.86 - 0.86|
|Low:||0.68 - 0.69||0.69 - 0.69|
|Close:||0.71 - 0.72||0.72 - 0.73|
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||5 (M)|
|Held by Insiders||1.49e+007 (%)|
|Held by Institutions||0 (%)|
|Shares Short||45 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-5 %|
|Return on Assets (ttm)||419.5 %|
|Return on Equity (ttm)||-95.9 %|
|Qtrly Rev. Growth||692000 %|
|Gross Profit (p.s.)||-42.92|
|Sales Per Share||-81.34|
|Qtrly Earnings Growth||-7.9 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-35 (M)|
|Price to Book value||0|
|Price to Sales||-0.01|
|Price to Cash Flow||-0|
|Dividend Pay Date||2019-03-28|
|Ex-Dividend Date||Invalid DateTime.|